TRCT
CTXR icon

Tower Research Capital (TRC)’s Citius Pharmaceuticals CTXR Stock Holding History

Tower Research Capital (TRC)’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65K Sell
2,724
-61
-2% -$41 ﹤0.01% 4786
2026
Q1 		$2.51K Sell
2,785
-23
-0.8% -$19 ﹤0.01% 4466
2025
Q4 		$2.18K Buy
+2,808
New +$3.51K ﹤0.01% 4572
2025
Q2 		– Sell
-4,410
Closed -$6.57K – 5301
2025
Q1 		$6.57K Sell
4,410
-3,802
-46% -$9.1K ﹤0.01% 4032
2024
Q4 		$32.8K Buy
8,212
+8,050
+4,969% +$54.2K ﹤0.01% 2835
2024
Q3 		$2.02K Sell
162
-1,579
-91% -$26.6K ﹤0.01% 5060
2024
Q2 		$25.4K Buy
1,741
+1,413
+431% +$25.3K ﹤0.01% 3606
2024
Q1 		$7.35K Sell
328
-199
-38% -$3.63K ﹤0.01% 4220
2023
Q4 		$9.97K Sell
527
-129
-20% -$2.45K ﹤0.01% 4316
2023
Q3 		$11.2K Buy
656
+297
+83% +$7.06K ﹤0.01% 4021
2023
Q2 		$10.8K Buy
+359
New +$11.8K ﹤0.01% 4066
2023
Q1 		– Sell
-22
Closed – – 5875
2022
Q4 		$0 Sell
22
-137
-86% -$3.74K ﹤0.01% 5950
2022
Q3 		$5K Buy
+159
New +$4.37K ﹤0.01% 5131
2022
Q2 		– Sell
-267
Closed -$12K – 6131
2022
Q1 		$12K Sell
267
-188
-41% -$7.42K ﹤0.01% 4049
2021
Q4 		$17K Buy
455
+80
+21% +$3.63K ﹤0.01% 3840
2021
Q3 		$19K Sell
375
-29
-7% -$1.46K ﹤0.01% 3750
2021
Q2 		$35K Sell
404
-1,610
-80% -$96.8K ﹤0.01% 3320
2021
Q1 		$90K Buy
+2,014
New +$80.2K ﹤0.01% 2668
2020
Q4 		– Sell
-337
Closed -$9K – 5155
2020
Q3 		$9K Sell
337
-772
-70% -$21.8K ﹤0.01% 4132
2020
Q2 		$31K Buy
+1,109
New +$24.3K ﹤0.01% 3412

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

Tower Research Capital (TRC)'s CTXR Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Citius Pharmaceuticals (CTXR) stake by 2.2% in Q2 2026, selling an estimated $41 and leaving 2,724 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #4786.

Tower Research Capital (TRC) first reported a position in CTXR in Q2 2020 and has held it in 20 quarters since. The position peaked at $90K in Q1 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Tower Research Capital (TRC) held 2,724 shares of Citius Pharmaceuticals worth $1.65K as of Q2 2026.
  • Tower Research Capital (TRC) sold 61 Citius Pharmaceuticals shares in Q2 2026, an estimated $41.
  • Citius Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4786 holding.
  • Tower Research Capital (TRC) first reported a position in Citius Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Citius Pharmaceuticals position peaked at $90K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.